Stress response, tachykinin, and cutaneous inflammation.
In the last decade, several new aspects of glucocorticoid (GC)-actions on immune cells have been recognized. This recognition has been largely obtained through clinical observations of stress-induced exacerbations of certain dermatologic diseases. To clarify whether GC modulates cutaneous inflammatory reactions besides its known anti-inflammatory effect, first we examined the effect of long-term application of topical GC on several kinds of inflammatory responses induced in the murine model and demonstrated that these regimens significantly augmented the classical contact sensitivity reaction, the croton oil-induced irritant reaction, and the IgE-mediated biphasic cutaneous reaction. In addition, large dose topical steroid and its withdrawal enhanced scratching behavior in hapten-challenged mice. This augmented scratching behavior correlated with the induction of preprotachykinin mRNA expression in the challenged skin. In an in vitro experiment, a low-dose, stress-induced level of glucocorticoid significantly upregulated hapten-induced proinflammatory cytokine (IL1alpha) production by murine keratinocyte cell line Pam 212 and induced substance P peptide production from cultured human keratinocytes. Our results suggest that unsuitable use of GC in addition to stress-induced GC may modulate immune function in the skin through aberrant production of tachykinin, such as substance P or other epidermal cell derived cytokines.
Katayama
I
I
Department of Dermatology, Nagasaki University School of Medicine, Sakamoto, Japan.
Bae
S J
SJ
Hamasaki
Y
Y
Igawa
K
K
Miyazaki
Y
Y
Yokozeki
H
H
Nishioka
K
K
D000818:Animals; D003872:Dermatitis / Q000209:etiology*; D003877:Dermatitis, Contact / Q000209:etiology / Q000517:prevention & control; D004305:Dose-Response Relationship, Drug; D005938:Glucocorticoids / Q000008:administration & dosage / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis; D016328:NF-kappa B / Q000502:physiology; D011537:Pruritus / Q000209:etiology; D013312:Stress, Physiological / Q000150:complications* / Q000378:metabolism*; D015320:Tachykinins / Q000502:physiology*; D018808:Transcription Factor AP-1 / Q000502:physiology
D005938:Glucocorticoids; D007375:Interleukin-1; D016328:NF-kappa B; D015320:Tachykinins; D018808:Transcription Factor AP-1